Advisory Committees Review Over One-Third Of NMEs, FDA Tells Sen. Frist
Executive Summary
FDA took just over one-third of eligible new molecular entities to an advisory committee, the agency indicated in a response to questions posed by the Senate Health, Education, Labor & Pensions Committee.